Gennex Laboratories
- Market cap
- ₹ 198 Cr.
- P/E
- 11.8x
- P/B
- 0.9x
- 52-week range
- 7.05 – 17.25
- ROE
- 9%
- ROCE
- 11%
- Dividend yield
- 0%
- Debt / equity
- 0.21
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- BSE
About
Gennex Laboratories Limited is an India-based active pharmaceutical ingredient manufacturing company. The Company is engaged in the business of manufacturing of bulk drugs and intermediaries. It offers products in various therapeutic categories, including expectorant (mucolyte), relaxant (skeletal muscle relaxant), antihistamines, urinary tract analgesic, antifungals called triazoles, tricyclic antidepressant, acting muscle relaxants, muscle relaxant, selective serotonin reuptake inhibitors (SSRIS), and xanthine oxidase inhibitors. Its products include Guaifenesin, Methocarbamol, Fexofenadine Hcl, Phenazopyridine Hcl, Fluconazole, Melitracen Hcl, Mephenesin, Chlorphenesin, Sertraline Hcl and Allopurinol. The Company has manufacturing facilities in India which cater to both domestic and international markets. Its international markets include Bangladesh, Bolivia, China, Colombia, Costa Rica, Cuba, Germany, Indonesia, Iran, Iraq, Israel, Jordan, Kenya, South Korea, Malaysia and Mexico.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Gennex Laboratories against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)11.8 against a typical 34.6: cheaper than most peers (1st = cheapest).31st of 220
- Sales growth+16.6% against a typical +15.6% from a year earlier.94th of 197
- Profit growth−6.8% against a typical +18.9% from a year earlier.106th of 160
- Share price, 3 months+2.5% against a typical −0.5%.80th of 200
- Size₹ 197.9 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).119th of 199
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 18 | 21 | 36 | 28 | 33 | 40 | 40 | 34 | 39 | 43 | 61 | 40 |
| Expenses | 12 | 17 | 29 | 24 | 26 | 33 | 38 | 29 | 32 | 34 | 55 | 35 |
| Operating Profit | 6 | 5 | 6 | 4 | 7 | 7 | 2 | 5 | 8 | 9 | 6 | 4 |
| OPM % | 31.7% | 22.4% | 17.6% | 14.9% | 22.4% | 17.9% | 5% | 14.8% | 19.2% | 20% | 9.7% | 11% |
| Other Income | 0 | 0 | 0 | 2 | 0 | 0 | 4 | 2 | 0 | −0 | 1 | 2 |
| Interest | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |
| Profit before tax | 4 | 4 | 5 | 6 | 6 | 6 | 4 | 6 | 6 | 7 | 5 | 5 |
| Tax % | 22.5% | 21.3% | 15.3% | 15.4% | 12.2% | 12.9% | 22.2% | 14.5% | 9.1% | 9.8% | 4.5% | 5.1% |
| Net Profit | 3 | 3 | 5 | 5 | 5 | 5 | 3 | 5 | 6 | 6 | 4 | 5 |
| EPS in Rs | 0.17 | 0.15 | 0.2 | 0.19 | 0.21 | 0.2 | 0.1 | 0.2 | 0.21 | 0.22 | 0.15 | 0.18 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 24%
- 3 Years
- 38%
- TTM
- 24%
- 10 Years
- —
- 5 Years
- 34%
- 3 Years
- 57%
- TTM
- 14%
- 10 Years
- 6%
- 5 Years
- 10%
- 3 Years
- 12%
- TTM
- —
- 10 Years
- 9%
- 5 Years
- 10%
- 3 Years
- 10%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Gennex Laboratories | ₹ 9.09 | ₹ 198 Cr. | 11.8x | 0.9x | 9% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- K. V. L. N. Bhaswanth
- Chief Operating Officer, Compliance Officer
- Arihant Baid
- Managing Director, Director
- Tiruvarur Muralidharan Gopalakrishnan
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.